These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 17910954)
21. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Asanuma M; Miyazaki I; Ogawa N Neurotox Res; 2003; 5(3):165-76. PubMed ID: 12835121 [TBL] [Abstract][Full Text] [Related]
22. Chronic intermittent L-DOPA treatment induces changes in dopamine release. Lundblad M; af Bjerkén S; Cenci MA; Pomerleau F; Gerhardt GA; Strömberg I J Neurochem; 2009 Feb; 108(4):998-1008. PubMed ID: 19196428 [TBL] [Abstract][Full Text] [Related]
23. Cyclooxygenase-independent neuroprotective effects of aspirin against dopamine quinone-induced neurotoxicity. Asanuma M; Miyazaki I; Kikkawa Y; Kimoto N; Takeshima M; Murakami S; Miyoshi K Neurochem Res; 2012 Sep; 37(9):1944-51. PubMed ID: 22674083 [TBL] [Abstract][Full Text] [Related]
24. Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Kuhn DM; Francescutti-Verbeem DM; Thomas DM Ann N Y Acad Sci; 2006 Aug; 1074():31-41. PubMed ID: 17105901 [TBL] [Abstract][Full Text] [Related]
25. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Buck K; Ferger B Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284 [TBL] [Abstract][Full Text] [Related]
26. Amphetamine reduces vesicular dopamine content in dexamethasone-differentiated PC12 cells only following L-DOPA exposure. Hondebrink L; Meulenbelt J; Timmerman JG; van den Berg M; Westerink RH J Neurochem; 2009 Oct; 111(2):624-33. PubMed ID: 19702656 [TBL] [Abstract][Full Text] [Related]
27. Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter. Arai A; Tomiyama M; Kannari K; Kimura T; Suzuki C; Watanabe M; Kawarabayashi T; Shen H; Shoji M Synapse; 2008 Aug; 62(8):632-5. PubMed ID: 18509855 [TBL] [Abstract][Full Text] [Related]
28. Metal-catalyzed oxidation of protein-bound dopamine. Akagawa M; Ishii Y; Ishii T; Shibata T; Yotsu-Yamashita M; Suyama K; Uchida K Biochemistry; 2006 Dec; 45(50):15120-8. PubMed ID: 17154550 [TBL] [Abstract][Full Text] [Related]
29. Tissue-dependent preventive effect of metallothionein against DNA damage in dyslipidemic mice under repeated stresses of fasting or restraint. Higashimoto M; Isoyama N; Ishibashi S; Inoue M; Takiguchi M; Suzuki S; Ohnishi Y; Sato M Life Sci; 2009 Apr; 84(17-18):569-75. PubMed ID: 19217914 [TBL] [Abstract][Full Text] [Related]
31. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. Shin JY; Park HJ; Ahn YH; Lee PH J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187 [TBL] [Abstract][Full Text] [Related]
32. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Asanuma M; Miyazaki I; Diaz-Corrales FJ; Miyoshi K; Ogawa N; Murata M Neurosci Res; 2008 Jan; 60(1):106-13. PubMed ID: 18022268 [TBL] [Abstract][Full Text] [Related]
33. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. Zhou G; Li X; Hein DW; Xiang X; Marshall JP; Prabhu SD; Cai L J Am Coll Cardiol; 2008 Aug; 52(8):655-66. PubMed ID: 18702970 [TBL] [Abstract][Full Text] [Related]
34. Metallothionein I,II deficient mice do not exhibit significantly worse long-term behavioral outcomes following neonatal hypoxia-ischemia: MT-I,II deficient mice have inherent behavioral impairments. McAuliffe JJ; Joseph B; Hughes E; Miles L; Vorhees CV Brain Res; 2008 Jan; 1190():175-85. PubMed ID: 18083145 [TBL] [Abstract][Full Text] [Related]
35. Novel codrugs with GABAergic activity for dopamine delivery in the brain. Denora N; Cassano T; Laquintana V; Lopalco A; Trapani A; Cimmino CS; Laconca L; Giuffrida A; Trapani G Int J Pharm; 2012 Nov; 437(1-2):221-31. PubMed ID: 22940209 [TBL] [Abstract][Full Text] [Related]
36. Cytotoxicities and induction of metallothionein (MT) and metal regulatory element (MRE)-binding transcription factor-1 (MTF-1) messenger RNA levels in the zebrafish (Danio rerio) ZFL and SJD cell lines after exposure to various metal ions. Cheuk WK; Chan PC; Chan KM Aquat Toxicol; 2008 Aug; 89(2):103-12. PubMed ID: 18639347 [TBL] [Abstract][Full Text] [Related]
37. Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease. Muramatsu S; Okuno T; Suzuki Y; Nakayama T; Kakiuchi T; Takino N; Iida A; Ono F; Terao K; Inoue N; Nakano I; Kondo Y; Tsukada H Synapse; 2009 Jul; 63(7):541-8. PubMed ID: 19253400 [TBL] [Abstract][Full Text] [Related]
38. Metallothionein-I/II double knockout mice are no more sensitive to the carcinogenic effects of nickel subsulfide than wild-type mice. Waalkes MP; Liu J; Kasprzak KS; Diwan BA Int J Toxicol; 2005; 24(4):215-20. PubMed ID: 16126615 [TBL] [Abstract][Full Text] [Related]
39. Stable overexpression of human metallothionein-IIA in a heart-derived cell line confers oxidative protection. Xue W; Liu Q; Cai L; Wang Z; Feng W Toxicol Lett; 2009 Jul; 188(1):70-6. PubMed ID: 19433272 [TBL] [Abstract][Full Text] [Related]
40. Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. Ebadi M; Sharma S Exp Biol Med (Maywood); 2006 Oct; 231(9):1576-83. PubMed ID: 17018883 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]